[Risk classification assures safety].
D002243:Carbolines / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000075202:Contraindications; D003925:Diabetic Angiopathies / Q000145:classification / Q000150:complications / Q000188:drug therapy*; D006331:Heart Diseases / Q000145:classification / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000145:classification / Q000150:complications / Q000188:drug therapy*; D018783:Impotence, Vasculogenic / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment; D000068581:Tadalafil
D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil
Risikostratifizierung schafft Sicherheit.